U.S. markets closed

Baxter International Inc. (BAX)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
81.05-0.90 (-1.10%)
At close: 4:00PM EDT
81.05 +0.03 (0.04%)
After hours: 04:08PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close81.95
Open82.23
Bid81.16 x 800
Ask81.17 x 1200
Day's Range81.01 - 82.39
52 Week Range73.12 - 88.32
Volume2,419,939
Avg. Volume3,337,434
Market Cap40.518B
Beta (5Y Monthly)0.66
PE Ratio (TTM)37.20
EPS (TTM)2.18
Earnings DateOct 27, 2021 - Nov 01, 2021
Forward Dividend & Yield1.12 (1.36%)
Ex-Dividend DateSep 02, 2021
1y Target Est94.21
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-4% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Baxter International Inc.
    Analyst Report: Baxter International Inc.Based in Deerfield, Illinois, Baxter International provides critical care, nutrition, renal, hospital, and surgical products. Baxter has approximately 50,000 employees and manufacturing operations in more than 20 countries. It is also a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Miromatrix Welcomes Dr. John Barry as Vice President of Research and Development

    EDEN PRAIRIE, Minn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced the hiring of Dr. John Barry as Vice President of Research and Development. Dr. Barry will be leading the activities for the development of the Company's transplantable liver and kidney programs including the use of a bio-engineered liver in an

  • Zacks

    Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How

    Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.

  • GlobeNewswire

    (HRC): Johnson Fistel Investigates Proposed Sale of Hill-Rom; Are Shareholders Getting a Fair Deal?

    SAN DIEGO, Sept. 04, 2021 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Hill-Rom Holdings (NYSE: HRC) ("Hill-Rom" or the "Company") breached their fiduciary duties in connection with the proposed sale of the Company to Baxter International Inc. ("Baxter") (NYSE: BAX). On September 3, 2021, Hill-Rom announced entering into a merger agreement with Baxter. Under the agreement terms, Baxter will acquire all of the